O'Dowd Brian F, Ji Xiaodong, Alijaniaram Mohammad, Rajaram Ryan D, Kong Michael M C, Rashid Asim, Nguyen Tuan, George Susan R
Department of Pharmacology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
J Biol Chem. 2005 Nov 4;280(44):37225-35. doi: 10.1074/jbc.M504562200. Epub 2005 Aug 22.
G protein-coupled receptors occur as dimers within arrays of oligomers. We visualized ensembles of dopamine receptor oligomers in living cells and evaluated the contributions of receptor conformation to the dynamics of oligomer association and dissociation, using a strategy of trafficking a receptor to another cellular compartment. We incorporated a nuclear localization sequence into the D1 dopamine receptor, which translocated from the cell surface to the nucleus. Receptor inverse agonists blocked this translocation, retaining the modified receptor, D1-nuclear localization signal (NLS), at the cell surface. D1 co-translocated with D1-NLS to the nucleus, indicating formation of homooligomers. (+)-Butaclamol retained both receptors at the cell surface, and removal of the drug allowed translocation of both receptors to the nucleus. Agonist-nonbinding D1(S198A/S199A)-NLS, containing two substituted serine residues in transmembrane 5 also oligomerized with D1, and both were retained on the cell surface by (+)-butaclamol. Drug removal disrupted these oligomerized receptors so that D1 remained at the cell surface while D1(S198A/S199A)-NLS trafficked to the nucleus. Thus, receptor conformational differences permitted oligomer disruption and showed that ligand-binding pocket occupancy by the inverse agonist induced a conformational change. We demonstrated robust heterooligomerization between the D2 dopamine receptor and the D1 receptor. The heterooligomers could not be disrupted by inverse agonists targeting either one of the receptor constituents. However, D2 did not heterooligomerize with the structurally modified D1(S198A/S199A), indicating an impaired interface for their interaction. Thus, we describe a novel method showing that a homogeneous receptor conformation maintains the structural integrity of oligomers, whereas conformational heterogeneity disrupts it.
G蛋白偶联受体以寡聚体阵列中的二聚体形式存在。我们对活细胞中多巴胺受体寡聚体进行了可视化,并使用将受体转运至另一个细胞区室的策略,评估了受体构象对寡聚体缔合和解离动力学的影响。我们将一个核定位序列引入D1多巴胺受体,该受体从细胞表面转运至细胞核。受体反向激动剂阻断了这种转运,使修饰后的受体D1-核定位信号(NLS)保留在细胞表面。D1与D1-NLS共转运至细胞核,表明形成了同源寡聚体。(+)-布他拉莫将两种受体都保留在细胞表面,去除该药物后,两种受体都能转运至细胞核。激动剂非结合型D1(S198A/S199A)-NLS在跨膜5区含有两个取代的丝氨酸残基,它也能与D1寡聚化,并且两者都被(+)-布他拉莫保留在细胞表面。去除药物会破坏这些寡聚化的受体,使得D1保留在细胞表面,而D1(S198A/S199A)-NLS转运至细胞核。因此,受体构象差异允许寡聚体解离,并且表明反向激动剂占据配体结合口袋会诱导构象变化。我们证明了D2多巴胺受体与D1受体之间存在强大的异源寡聚化。针对任何一种受体成分的反向激动剂都无法破坏这些异源寡聚体。然而,D2不能与结构修饰的D1(S198A/S199A)异源寡聚化,表明它们相互作用的界面受损。因此,我们描述了一种新方法,该方法表明同质的受体构象维持寡聚体的结构完整性,而异构象异质性则会破坏它。